WORCESTER, Mass. & ST. LOUIS--(BUSINESS WIRE)--May 1, 2006--U.S. Bank (NYSE:USB - News) has provided the financing to help develop a potentially life-saving therapeutic for non-Hodgkin's lymphoma, marking the first time the New Market Tax Credit (NMTC) program has been used to support a biopharmaceutical company. As part of a financing arranged with Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI - News), U.S. Bank purchased $4.6 million of NMTCs as part of an investment in a subsidiary of Biovest International, Inc. (OTCBB:BVTI - News). Biovest is an Accentia subsidiary developing the revolutionary cancer treatment.
